5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA

Matthew B. Pomrenze; Sam Vaillancourt; Juliana S. Salgado; Kendall B. Raymond; Pierre Llorach; Hiroaki Sacai; Daniel Ryskamp Rijsketic; Tuuli M. Hietamies; Gavin C. Touponse; Daniel F. Cardozo Pinto; Zahra Rastegar; Austen B. Casey; Neir Eshel; Robert C. Malenka; Boris D. Heifets

doi:10.1038/s41380-025-03128-4

journal article Open Access Jul 24, 2025

5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA

Matthew B. Pomrenze

Sam Vaillancourt Juliana S. Salgado

Kendall B. Raymond Pierre Llorach Hiroaki Sacai Daniel Ryskamp Rijsketic

Tuuli M. Hietamies Gavin C. Touponse

Daniel F. Cardozo Pinto

Zahra Rastegar Austen B. Casey

Neir Eshel

Robert C. Malenka

Boris D. Heifets

Molecular Psychiatry Vol. 30 No. 11 pp. 5405-5416 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41380-025-03128-4

Topics

No keywords indexed for this article. Browse by subject →

References

80

[1]

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Jennifer M. Mitchell, Michael Bogenschutz, Alia Lilienstein et al.

Nature Medicine 10.1038/s41591-021-01336-3

[2]

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Jennifer M. Mitchell, Marcela Ot’alora G., Bessel van der Kolk et al.

Nature Medicine 10.1038/s41591-023-02565-4

[3]

Heifets BD, Olson DE. Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology. 2024;49:104–18. 10.1038/s41386-023-01666-5

[4]

McCann UD, Ricaurte GA. Effects of MDMA on the Human Nervous System. The Effects of Drug Abuse on the Human Nervous System. Amsterdam: Elsevier; 2014. p. 475–97. 10.1016/b978-0-12-418679-8.00015-0

[5]

Shorter D, Hsieh J, Kosten TR. Pharmacologic management of comorbid post-traumatic stress disorder and addictions. Am J Addict. 2015;24:705–12. 10.1111/ajad.12306

[6]

De La Garza R, Fabrizio KR, Gupta A. Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology. 2007;189:425–34. 10.1007/s00213-005-0255-5

[7]

Wang Z, Woolverton WL. Estimating the relative reinforcing strength of (+/−)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology (Berl). 2007;189:483–8. 10.1007/s00213-006-0599-5

[8]

Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron. 2011;69:628–49. 10.1016/j.neuron.2011.02.010

[9]

Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther. 2002;95:73–88. 10.1016/s0163-7258(02)00234-6

[10]

Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, et al. Distinct neural mechanisms for the prosocial and rewarding properties of MDMA. Sci Transl Med. 2019;11:eaaw6435. 10.1126/scitranslmed.aaw6435

[11]

Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019;569:116–20. 10.1038/s41586-019-1075-9

[12]

Walsh JJ, Christoffel DJ, Heifets BD, Ben-Dor GA, Selimbeyoglu A, Hung LW, et al. 5-HT release in nucleus accumbens rescues social deficits in mouse autism model. Nature. 2018;560:589–94. 10.1038/s41586-018-0416-4

[13]

Walsh JJ, Llorach P, Cardozo Pinto DF, Wenderski W, Christoffel DJ, Salgado JS, et al. Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD. Neuropsychopharmacology. 2021;46:2000–10. 10.1038/s41386-021-01091-6

[14]

Rein B, Raymond K, Boustani C, Tuy S, Zhang J, St Laurent R, et al. MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens. Sci Adv. 2024;10:eadl6554. 10.1126/sciadv.adl6554

[15]

Kamilar-Britt P, Bedi G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. Neurosci Biobehav Rev. 2015;57:433–46. 10.1016/j.neubiorev.2015.08.016

[16]

Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9:1645–52. 10.1093/scan/nst161

[17]

Bershad AK, Miller MA, Baggott MJ, de Wit H. The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants? J Psychopharmacol. 2016;30:1248–58. 10.1177/0269881116663120

[18]

Vidal-Infer A, Roger-Sánchez C, Daza-Losada M, Aguilar MA, Miñarro J, Rodríguez-Arias M. Role of the dopaminergic system in the acquisition, expression and reinstatement of MDMA-induced conditioned place preference in adolescent mice. PLoS One. 2012;7:e43107. 10.1371/journal.pone.0043107

[19]

Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse. 2005;55:242–51. 10.1002/syn.20109

[20]

De Deurwaerdère P, Spampinato U. Role of Serotonin2A and Serotonin2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem. 1999;73:1033–42. 10.1046/j.1471-4159.1999.0731033.x

[21]

Deurwaerdère PD, Navailles S, Berg KA, Clarke WP, Spampinato U. Constitutive activity of the Serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci. 2004;24:3235–41. 10.1523/jneurosci.0112-04.2004

[22]

Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse. 2000;35:53–61. 10.1002/(sici)1098-2396(200001)35:1<53::aid-syn7>3.0.co;2-2

[23]

Rothman RB, Baumann MH. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci. 2006;1074:245–60. 10.1196/annals.1369.064

[24]

Schenk S, Highgate Q. Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse. J Neurochem. 2021;157:1714–24. 10.1111/jnc.15348

[25]

Li Y, Simmler LD, Van Zessen R, Flakowski J, Wan J-X, Deng F, et al. Synaptic mechanism underlying serotonin modulation of transition to cocaine addiction. Science. 2021;373:1252–6. 10.1126/science.abi9086

[26]

Federici M, Sebastianelli L, Natoli S, Bernardi G, Mercuri NB. Electrophysiologic changes in ventral midbrain dopaminergic neurons resulting from (+/−) -3,4-Methylenedioxymethamphetamine (MDMA—“Ecstasy”). Biol Psychiatry. 2007;62:680–6. 10.1016/j.biopsych.2006.11.019

[27]

O’Dell LE, Parsons LH. Serotonin1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J Pharmacol Exp Ther. 2004;311:711–9. 10.1124/jpet.104.069278

[28]

Fletcher PJ, Chintoh AF, Sinyard J, Higgins GA. Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Neuropsychopharmacology. 2004;29:308–18. 10.1038/sj.npp.1300319

[29]

Navailles S, Moison D, Cunningham KA, Spampinato U. Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology. 2008;33:237–46. 10.1038/sj.npp.1301414

[30]

Canal CE, Murnane KS. The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. J Psychopharmacol. 2017;31:127–43. 10.1177/0269881116677104

[31]

Fletcher PJ, Azampanah A, Korth KM. Activation of 5-HT(1B) receptors in the nucleus accumbens reduces self-administration of amphetamine on a progressive ratio schedule. Pharmacol Biochem Behav. 2002;71:717–25. 10.1016/s0091-3057(01)00717-1

[32]

Fletcher PJ, Korth KM. Activation of 5-HT1B receptors in the nucleus accumbens reduces amphetamine-induced enhancement of responding for conditioned reward. Psychopharmacology (Berl). 1999;142:165–74. 10.1007/s002130050876

[33]

Zayara AE, McIver G, Valdivia PN, Lominac KD, McCreary AC, Szumlinski KK. Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology (Berl). 2011;213:321–35. 10.1007/s00213-010-1996-3

[34]

Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, et al. The central serotonin2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem. 2010;114:1323–32. 10.1111/j.1471-4159.2010.06848.x

[35]

Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay J-M, et al. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci. 2008;28:2933–40. 10.1523/jneurosci.5723-07.2008

[36]

Howell LL, Cunningham KA. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev. 2015;67:176–97. 10.1124/pr.114.009514

[37]

Devroye C, Filip M, Przegaliński E, McCreary AC, Spampinato U. Serotonin2C receptors and drug addiction: focus on cocaine. Exp Brain Res. 2013;230:537–45. 10.1007/s00221-013-3593-2

[38]

Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants

Isabelle Straumann, Isidora Avedisian, Aaron Klaiber et al.

Neuropsychopharmacology 2024 10.1038/s41386-024-01972-6

[39]

Chen X, Ye R, Gargus JJ, Blakely RD, Dobrenis K, Sze JY. Disruption of transient serotonin accumulation by non-serotonin-producing neurons impairs cortical map development. Cell Rep. 2015;10:346–58. 10.1016/j.celrep.2014.12.033

[40]

Wu X, Morishita W, Beier KT, Heifets BD, Malenka RC. 5-HT modulation of a medial septal circuit tunes social memory stability. Nature. 2021;599:96–101. 10.1038/s41586-021-03956-8

[41]

Pomrenze MB, Cardozo Pinto DF, Neumann PA, Llorach P, Tucciarone JM, Morishita W, et al. Modulation of 5-HT release by dynorphin mediates social deficits during opioid withdrawal. Neuron. 2022;110:4125–4143.e6. 10.1016/j.neuron.2022.09.024

[42]

A high-resolution transcriptomic and spatial atlas of cell types in the whole mouse brain

Zizhen Yao, Cindy van Velthoven, Michael Kunst et al.

Nature 2023 10.1038/s41586-023-06812-z

[43]

Rijsketic DR, Casey AB, Barbosa DAN, Zhang X, Hietamies TM, Ramirez-Ovalle G, et al. UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacol. 2023;48:1798–807. https://doi.org/10.1038/s41386-023-01613-4 10.1038/s41386-023-01613-4

[44]

Esaki H, Sasaki Y, Nishitani N, Kamada H, Mukai S, Ohshima Y, et al. Role of 5-HT1A receptors in the basolateral amygdala on 3,4-methylenedioxymethamphetamine-induced prosocial effects in mice. Eur J Pharmacol. 2023;946:175653. 10.1016/j.ejphar.2023.175653

[45]

Curry DW, Young MB, Tran AN, Daoud GE, Howell LL. Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Neuropharmacology. 2018;128:196–206. 10.1016/j.neuropharm.2017.10.003

[46]

Gudelsky GA, Nash JF. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem. 1996;66:243–9. 10.1046/j.1471-4159.1996.66010243.x

[47]

Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, L. Murphy D, R. Uhl G, et al. Effects of MDMA on extracellular dopamine and serotonin levels in mice lacking dopamine and/or serotonin transporters. Curr Neuropharm. 2011;9:91–95. 10.2174/157015911795017254

[48]

Bankson MG, Yamamoto BK. Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem. 2004;91:852–9. 10.1111/j.1471-4159.2004.02763.x

[49]

Lammel S, Steinberg EE, Földy C, Wall NR, Beier K, Luo L, et al. Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons. Neuron. 2015;85:429–38. 10.1016/j.neuron.2014.12.036

[50]

Bäckman CM, Malik N, Zhang Y, Shan L, Grinberg A, Hoffer BJ, et al. Characterization of a mouse strain expressing Cre recombinase from the 3’ untranslated region of the dopamine transporter locus. Genesis. 2006;44:383–90. 10.1002/dvg.20228

Showing 50 of 80 references

Metrics

8

Citations

80

References

Details

Published: Jul 24, 2025
Vol/Issue: 30(11)
Pages: 5405-5416
License: View

Authors

Daniel Ryskamp Rijsketic

Daniel F. Cardozo Pinto

Departments of Cellular and Molecular Pharmacology, Physiology, and Psychiatry, The University of California, San Francisco, San Francisco, CA, 94143; and Department of Molecular Biology, Princeton University, Princeton, NJ 08544

B

Boris D. Heifets

Funding

Burroughs Wellcome Fund

U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse Award: DA042012

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health Award: MH130591

Simons Foundation Bridge to Independence Award

Cite This Article

Matthew B. Pomrenze, Sam Vaillancourt, Juliana S. Salgado, et al. (2025). 5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA. Molecular Psychiatry, 30(11), 5405-5416. https://doi.org/10.1038/s41380-025-03128-4

5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA

You May Also Like